New safety check for Kids' leukemia drug BESPONSA
NCT ID NCT06476665
First seen Apr 30, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study looks at the safety of BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL) that has come back or not responded to treatment. Researchers will track side effects and liver problems for up to a year. About 10 children who have never used BESPONSA before will receive the drug as prescribed by their doctor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.